Whitehawk Therapeutics, Inc. Common Stock WHWK Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$115.81M-519% | -$20.6M+67.7% | -$15.62M+74.7% | -$10.42M+84.1% | $27.61M+140% | ||
| $22.9K-88.6% | $78.9K-59.2% | $124.9K-34.4% | $166K-11.5% | $200.3K+10.7% | ||
| $10.39M+16.3% | $9.87M-8.9% | $9.34M-22.8% | $9.18M-27.1% | $8.93M-30.3% | ||
| -$177K-100% | $87.27M— | $87.27M— | $87.44M— | $87.44M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$546K— | $3.92M— | —— | —— | —— | ||
| —— | —— | —— | $501K+201% | -$494K+8.5% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | -$475K+5.8% | ||
| -$107.78M-108% | -$97.43M-63.6% | -$95.25M-75.9% | -$95.56M-89.6% | -$51.76M+10.8% | ||
| —— | —— | —— | $926K-71.0% | $1.47M-56.1% | ||
| $167.87M+482% | $148.69M+308% | $125.77M+150% | $42.14M-38.0% | $28.84M-41.2% | ||
| $83.77M+41.8% | $59.85M-5.5% | $33.4M-51.2% | $46.6M-50.7% | $59.09M-54.5% | ||
| —— | —— | —— | —— | $101.36M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $26K+1,200% | $21K-70.0% | ||
| —— | —— | —— | —— | $95.34M— | ||
| —— | —— | —— | —— | $173.73M— | ||
| $1.89M+120% | $1.53M+17.4% | $879K-45.2% | $471K-75.0% | $860K-63.5% | ||
| —— | —— | —— | —— | —— | ||
| -$177K-100% | $87.27M— | $87.27M— | $87.44M— | $87.44M— | ||
| —— | —— | —— | —— | -$475K+5.8% | ||
| -$271K+89.7% | $434K+115% | -$149K+95.9% | -$1.29M+75.1% | -$2.63M+49.5% | ||
| —— | —— | —— | —— | $419K— | ||
| —— | —— | —— | —— | $101.36M— | ||
| $83.77M+41.8% | $59.85M-5.5% | $33.4M-51.2% | $46.6M-50.7% | $59.09M-54.5% | ||
| —— | —— | —— | $5.63M— | $4.82M— | ||
| —— | —— | —— | —— | $100M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | -$475K+5.8% | ||
| —— | —— | —— | —— | —— | ||
| -$107.78M-102% | -$97.99M-60.1% | -$95.99M-70.1% | -$96.49M-80.0% | -$53.23M+13.2% | ||
| -$107.78M-102% | -$97.99M-60.1% | -$95.99M-70.1% | -$96.49M-80.0% | -$53.23M+13.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Whitehawk Therapeutics, Inc. Common Stock generate?
- Whitehawk Therapeutics, Inc. Common Stock (WHWK) generated -$107.8M in operating cash flow over the trailing twelve months.
- What is Whitehawk Therapeutics, Inc. Common Stock's free cash flow?
- After $738.0K of capital expenditures, Whitehawk Therapeutics, Inc. Common Stock's free cash flow was -$107.8M over the trailing twelve months, down 102.5% year over year.
- Where does Whitehawk Therapeutics, Inc. Common Stock's cash flow data come from?
- Every line is extracted from Whitehawk Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.